HEADER IMMUNE SYSTEM/PEPTIDE INHIBITOR 12-OCT-99 1D5Z TITLE X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH PEPTIDOMIMETIC AND TITLE 2 SEB COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEIN (HLA CLASS II HISTOCOMPATIBILITY ANTIGEN); COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: DR ALPHA CHAIN, EXTRACELLULAR DOMAIN; COMPND 5 SYNONYM: HLA-DR4; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: PROTEIN (HLA CLASS II HISTOCOMPATIBILITY ANTIGEN); COMPND 9 CHAIN: B; COMPND 10 FRAGMENT: DR-4 BETA CHAIN, EXTRACELLULAR DOMAIN; COMPND 11 SYNONYM: HLA-DR4; COMPND 12 ENGINEERED: YES; COMPND 13 MOL_ID: 3; COMPND 14 MOLECULE: PROTEIN (ENTEROTOXIN TYPE B); COMPND 15 CHAIN: C; COMPND 16 SYNONYM: SEB, SUPERANTIGEN; COMPND 17 MOL_ID: 4; COMPND 18 MOLECULE: PROTEIN (PEPTIDOMIMETIC INHIBITOR); COMPND 19 CHAIN: D; COMPND 20 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: DROSOPHILA MELANOGASTER; SOURCE 6 EXPRESSION_SYSTEM_COMMON: FRUIT FLY; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7227; SOURCE 8 MOL_ID: 2; SOURCE 9 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 10 ORGANISM_COMMON: HUMAN; SOURCE 11 ORGANISM_TAXID: 9606; SOURCE 12 EXPRESSION_SYSTEM: DROSOPHILA MELANOGASTER; SOURCE 13 EXPRESSION_SYSTEM_COMMON: FRUIT FLY; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 7227; SOURCE 15 MOL_ID: 3; SOURCE 16 ORGANISM_SCIENTIFIC: STAPHYLOCOCCUS AUREUS; SOURCE 17 ORGANISM_TAXID: 1280; SOURCE 18 MOL_ID: 4; SOURCE 19 SYNTHETIC: YES; SOURCE 20 OTHER_DETAILS: THE PEPTIDE WAS CHEMICALLY SYNTHESIZED. KEYWDS MHC CLASS II-SUPERANTIGEN COMPLEX, IMMUNE SYSTEM-PEPTIDE INHIBITOR KEYWDS 2 COMPLEX, PEPTIDOMIMETIC INHIBITOR EXPDTA X-RAY DIFFRACTION AUTHOR A.SWAIN,R.CROWTHER,U.KAMMLOTT REVDAT 7 15-NOV-23 1D5Z 1 LINK ATOM REVDAT 6 20-SEP-23 1D5Z 1 REMARK REVDAT 5 31-MAY-23 1D5Z 1 LINK REVDAT 4 13-JUL-11 1D5Z 1 VERSN REVDAT 3 24-FEB-09 1D5Z 1 VERSN REVDAT 2 01-APR-03 1D5Z 1 JRNL REVDAT 1 28-JUN-00 1D5Z 0 JRNL AUTH D.R.BOLIN,A.L.SWAIN,R.SARABU,S.J.BERTHEL,P.GILLESPIE, JRNL AUTH 2 N.J.HUBY,R.MAKOFSKE,L.ORZECHOWSKI,A.PERROTTA,K.TOTH, JRNL AUTH 3 J.P.COOPER,N.JIANG,F.FALCIONI,R.CAMPBELL,D.COX,D.GAIZBAND, JRNL AUTH 4 C.J.BELUNIS,D.VIDOVIC,K.ITO,R.CROWTHER,U.KAMMLOTT,X.ZHANG, JRNL AUTH 5 R.PALERMO,D.WEBER,J.GUENOT,Z.NAGY,G.L.OLSON JRNL TITL PEPTIDE AND PEPTIDE MIMETIC INHIBITORS OF ANTIGEN JRNL TITL 2 PRESENTATION BY HLA-DR CLASS II MHC MOLECULES. DESIGN, JRNL TITL 3 STRUCTURE-ACTIVITY RELATIONSHIPS, AND X-RAY CRYSTAL JRNL TITL 4 STRUCTURES. JRNL REF J.MED.CHEM. V. 43 2135 2000 JRNL REFN ISSN 0022-2623 JRNL PMID 10841792 JRNL DOI 10.1021/JM000034H REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 0.9 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 19.45 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 374134.830 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 94.1 REMARK 3 NUMBER OF REFLECTIONS : 50725 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.234 REMARK 3 FREE R VALUE : 0.265 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 10.100 REMARK 3 FREE R VALUE TEST SET COUNT : 5123 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.004 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.00 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.13 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 88.10 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 6982 REMARK 3 BIN R VALUE (WORKING SET) : 0.2530 REMARK 3 BIN FREE R VALUE : 0.2960 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 10.60 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 827 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.010 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4904 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 137 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 6.80 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 20.10 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 1.01000 REMARK 3 B22 (A**2) : 3.80000 REMARK 3 B33 (A**2) : -4.81000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.26 REMARK 3 ESD FROM SIGMAA (A) : 0.16 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.31 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.21 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.007 REMARK 3 BOND ANGLES (DEGREES) : 1.400 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 25.80 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.820 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.310 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.020 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 1.950 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 2.870 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.39 REMARK 3 BSOL : 33.87 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1D5Z COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 15-OCT-99. REMARK 100 THE DEPOSITION ID IS D_1000009825. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 01-JAN-94 REMARK 200 TEMPERATURE (KELVIN) : 113 REMARK 200 PH : 7.4 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : NSLS REMARK 200 BEAMLINE : X4A REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9686 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : FUJI REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 51927 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 96.2 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.06700 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: PDB ID CODE 1D5M REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.38 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.70 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 7.4 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 39.17150 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 50.08750 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 50.08400 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 50.08750 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 39.17150 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 50.08400 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TETRAMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 INHIBITOR WAS BOUND TO MHC; SUBSEQUENTLY COMPLEX WITH SEB WAS FORMED REMARK 400 REMARK 400 THE ACE-ALC-ARG-ALA-ODA-SER-LEU-NH2 IS PEPTIDE-LIKE, A MEMBER OF REMARK 400 INHIBITOR CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: ACE-ALC-ARG-ALA-ODA-SER-LEU-NH2 REMARK 400 CHAIN: D REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: NULL REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ILE A 1 REMARK 465 LYS A 2 REMARK 465 ASP A 181 REMARK 465 LYS B 105 REMARK 465 THR B 106 REMARK 465 GLN B 107 REMARK 465 PRO B 108 REMARK 465 LEU B 109 REMARK 465 GLN B 110 REMARK 465 HIS B 111 REMARK 465 HIS B 112 REMARK 465 ASN B 113 REMARK 465 ARG B 191 REMARK 465 SER B 192 REMARK 465 GLU C 1 REMARK 465 THR C 99 REMARK 465 ASN C 100 REMARK 465 ASP C 101 REMARK 465 ILE C 102 REMARK 465 ASN C 103 REMARK 465 SER C 104 REMARK 465 HIS C 105 REMARK 465 GLN C 106 REMARK 465 THR C 107 REMARK 465 ASP C 108 REMARK 465 LYS C 238 REMARK 465 LYS C 239 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG B 55 CG CD NE CZ NH1 NH2 REMARK 470 LYS C 109 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ODA D 807 CA - C - N ANGL. DEV. = 19.9 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 113 147.61 -170.28 REMARK 500 ASN B 19 72.70 42.90 REMARK 500 HIS B 33 -109.05 71.34 REMARK 500 THR B 90 -72.77 -127.28 REMARK 500 ASP C 42 -179.02 -173.50 REMARK 500 PHE C 44 -64.69 -99.58 REMARK 500 LEU C 58 19.73 -164.48 REMARK 500 LYS C 97 -122.90 -95.34 REMARK 500 ARG C 110 -169.97 179.22 REMARK 500 ASN C 179 -150.58 -143.89 REMARK 500 GLU C 193 17.86 54.26 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ODA D 807 SER D 808 -127.20 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 ODA D 807 32.47 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN D OF PROTEIN REMARK 800 (PEPTIDOMIMETIC INHIBITOR) REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1D5M RELATED DB: PDB REMARK 900 RELATED ID: 1D5X RELATED DB: PDB REMARK 900 RELATED ID: 1D6E RELATED DB: PDB DBREF 1D5Z A 1 181 UNP P01903 HA2R_HUMAN 26 206 DBREF 1D5Z B 1 192 UNP P13760 HB2H_HUMAN 30 221 DBREF 1D5Z C 1 239 UNP P01552 ETXB_STAAU 28 266 DBREF 1D5Z D 803 810 PDB 1D5Z 1D5Z 803 810 SEQRES 1 A 181 ILE LYS GLU GLU HIS VAL ILE ILE GLN ALA GLU PHE TYR SEQRES 2 A 181 LEU ASN PRO ASP GLN SER GLY GLU PHE MET PHE ASP PHE SEQRES 3 A 181 ASP GLY ASP GLU ILE PHE HIS VAL ASP MET ALA LYS LYS SEQRES 4 A 181 GLU THR VAL TRP ARG LEU GLU GLU PHE GLY ARG PHE ALA SEQRES 5 A 181 SER PHE GLU ALA GLN GLY ALA LEU ALA ASN ILE ALA VAL SEQRES 6 A 181 ASP LYS ALA ASN LEU GLU ILE MET THR LYS ARG SER ASN SEQRES 7 A 181 TYR THR PRO ILE THR ASN VAL PRO PRO GLU VAL THR VAL SEQRES 8 A 181 LEU THR ASN SER PRO VAL GLU LEU ARG GLU PRO ASN VAL SEQRES 9 A 181 LEU ILE CYS PHE ILE ASP LYS PHE THR PRO PRO VAL VAL SEQRES 10 A 181 ASN VAL THR TRP LEU ARG ASN GLY LYS PRO VAL THR THR SEQRES 11 A 181 GLY VAL SER GLU THR VAL PHE LEU PRO ARG GLU ASP HIS SEQRES 12 A 181 LEU PHE ARG LYS PHE HIS TYR LEU PRO PHE LEU PRO SER SEQRES 13 A 181 THR GLU ASP VAL TYR ASP CYS ARG VAL GLU HIS TRP GLY SEQRES 14 A 181 LEU ASP GLU PRO LEU LEU LYS HIS TRP GLU PHE ASP SEQRES 1 B 192 GLY ASP THR ARG PRO ARG PHE LEU GLU GLN VAL LYS HIS SEQRES 2 B 192 GLU CYS HIS PHE PHE ASN GLY THR GLU ARG VAL ARG PHE SEQRES 3 B 192 LEU ASP ARG TYR PHE TYR HIS GLN GLU GLU TYR VAL ARG SEQRES 4 B 192 PHE ASP SER ASP VAL GLY GLU TYR ARG ALA VAL THR GLU SEQRES 5 B 192 LEU GLY ARG PRO ASP ALA GLU TYR TRP ASN SER GLN LYS SEQRES 6 B 192 ASP LEU LEU GLU GLN LYS ARG ALA ALA VAL ASP THR TYR SEQRES 7 B 192 CYS ARG HIS ASN TYR GLY VAL GLY GLU SER PHE THR VAL SEQRES 8 B 192 GLN ARG ARG VAL TYR PRO GLU VAL THR VAL TYR PRO ALA SEQRES 9 B 192 LYS THR GLN PRO LEU GLN HIS HIS ASN LEU LEU VAL CYS SEQRES 10 B 192 SER VAL ASN GLY PHE TYR PRO GLY SER ILE GLU VAL ARG SEQRES 11 B 192 TRP PHE ARG ASN GLY GLN GLU GLU LYS THR GLY VAL VAL SEQRES 12 B 192 SER THR GLY LEU ILE GLN ASN GLY ASP TRP THR PHE GLN SEQRES 13 B 192 THR LEU VAL MET LEU GLU THR VAL PRO ARG SER GLY GLU SEQRES 14 B 192 VAL TYR THR CYS GLN VAL GLU HIS PRO SER LEU THR SER SEQRES 15 B 192 PRO LEU THR VAL GLU TRP ARG ALA ARG SER SEQRES 1 C 239 GLU SER GLN PRO ASP PRO LYS PRO ASP GLU LEU HIS LYS SEQRES 2 C 239 SER SER LYS PHE THR GLY LEU MET GLU ASN MET LYS VAL SEQRES 3 C 239 LEU TYR ASP ASP ASN HIS VAL SER ALA ILE ASN VAL LYS SEQRES 4 C 239 SER ILE ASP GLN PHE LEU TYR PHE ASP LEU ILE TYR SER SEQRES 5 C 239 ILE LYS ASP THR LYS LEU GLY ASN TYR ASP ASN VAL ARG SEQRES 6 C 239 VAL GLU PHE LYS ASN LYS ASP LEU ALA ASP LYS TYR LYS SEQRES 7 C 239 ASP LYS TYR VAL ASP VAL PHE GLY ALA ASN TYR TYR TYR SEQRES 8 C 239 GLN CYS TYR PHE SER LYS LYS THR ASN ASP ILE ASN SER SEQRES 9 C 239 HIS GLN THR ASP LYS ARG LYS THR CYS MET TYR GLY GLY SEQRES 10 C 239 VAL THR GLU HIS ASN GLY ASN GLN LEU ASP LYS TYR ARG SEQRES 11 C 239 SER ILE THR VAL ARG VAL PHE GLU ASP GLY LYS ASN LEU SEQRES 12 C 239 LEU SER PHE ASP VAL GLN THR ASN LYS LYS LYS VAL THR SEQRES 13 C 239 ALA GLN GLU LEU ASP TYR LEU THR ARG HIS TYR LEU VAL SEQRES 14 C 239 LYS ASN LYS LYS LEU TYR GLU PHE ASN ASN SER PRO TYR SEQRES 15 C 239 GLU THR GLY TYR ILE LYS PHE ILE GLU ASN GLU ASN SER SEQRES 16 C 239 PHE TRP TYR ASP MET MET PRO ALA PRO GLY ASP LYS PHE SEQRES 17 C 239 ASP GLN SER LYS TYR LEU MET MET TYR ASN ASP ASN LYS SEQRES 18 C 239 MET VAL ASP SER LYS ASP VAL LYS ILE GLU VAL TYR LEU SEQRES 19 C 239 THR THR LYS LYS LYS SEQRES 1 D 8 ACE ALC ARG ALA ODA SER LEU NH2 MODRES 1D5Z ALC D 804 ALA 2-AMINO-3-CYCLOHEXYL-PROPIONIC ACID HET ACE D 803 3 HET ALC D 804 11 HET ODA D 807 16 HET NH2 D 810 1 HETNAM ACE ACETYL GROUP HETNAM ALC 2-AMINO-3-CYCLOHEXYL-PROPIONIC ACID HETNAM ODA 9-AMINO-6,10-DIOXO-OCTAHYDRO-PYRIDAZINO[1,2-A][1, HETNAM 2 ODA 2]DIAZEPINE-1-CARBOXYLIC ACID HETNAM NH2 AMINO GROUP FORMUL 4 ACE C2 H4 O FORMUL 4 ALC C9 H17 N O2 FORMUL 4 ODA C10 H15 N3 O4 FORMUL 4 NH2 H2 N FORMUL 5 HOH *137(H2 O) HELIX 1 1 GLU A 47 ALA A 52 1 6 HELIX 2 2 GLN A 57 SER A 77 1 21 HELIX 3 3 THR B 51 LEU B 53 5 3 HELIX 4 4 GLY B 54 SER B 63 1 10 HELIX 5 5 GLN B 64 TYR B 78 1 15 HELIX 6 6 TYR B 78 GLU B 87 1 10 HELIX 7 7 SER B 88 THR B 90 5 3 HELIX 8 8 LYS C 13 LYS C 16 5 4 HELIX 9 9 MET C 21 VAL C 26 1 6 HELIX 10 10 LEU C 27 ASP C 29 5 3 HELIX 11 11 ASN C 70 ASP C 79 1 10 HELIX 12 12 ALA C 157 LYS C 173 1 17 HELIX 13 13 ASP C 209 MET C 215 1 7 HELIX 14 14 MET C 216 ASN C 220 5 5 SHEET 1 A 8 GLU A 40 TRP A 43 0 SHEET 2 A 8 ASP A 29 ASP A 35 -1 O HIS A 33 N VAL A 42 SHEET 3 A 8 SER A 19 PHE A 26 -1 O PHE A 22 N VAL A 34 SHEET 4 A 8 HIS A 5 ASN A 15 -1 N ILE A 8 O ASP A 25 SHEET 5 A 8 PHE B 7 PHE B 18 -1 O PHE B 7 N ASN A 15 SHEET 6 A 8 ARG B 23 TYR B 32 -1 O ARG B 23 N PHE B 18 SHEET 7 A 8 GLU B 35 ASP B 41 -1 O GLU B 35 N TYR B 32 SHEET 8 A 8 TYR B 47 ALA B 49 -1 N ARG B 48 O ARG B 39 SHEET 1 B 4 GLU A 88 THR A 93 0 SHEET 2 B 4 ASN A 103 PHE A 112 -1 N ILE A 106 O LEU A 92 SHEET 3 B 4 PHE A 145 PHE A 153 -1 N PHE A 145 O PHE A 112 SHEET 4 B 4 SER A 133 GLU A 134 -1 O SER A 133 N TYR A 150 SHEET 1 C 4 GLU A 88 THR A 93 0 SHEET 2 C 4 ASN A 103 PHE A 112 -1 N ILE A 106 O LEU A 92 SHEET 3 C 4 PHE A 145 PHE A 153 -1 N PHE A 145 O PHE A 112 SHEET 4 C 4 LEU A 138 PRO A 139 -1 N LEU A 138 O ARG A 146 SHEET 1 D 4 LYS A 126 VAL A 128 0 SHEET 2 D 4 ASN A 118 ARG A 123 -1 O TRP A 121 N VAL A 128 SHEET 3 D 4 VAL A 160 GLU A 166 -1 O ASP A 162 N LEU A 122 SHEET 4 D 4 LEU A 174 GLU A 179 -1 O LEU A 174 N VAL A 165 SHEET 1 E 4 GLU B 98 PRO B 103 0 SHEET 2 E 4 LEU B 115 PHE B 122 -1 N VAL B 116 O TYR B 102 SHEET 3 E 4 PHE B 155 LEU B 161 -1 N PHE B 155 O PHE B 122 SHEET 4 E 4 VAL B 142 SER B 144 -1 O VAL B 143 N MET B 160 SHEET 1 F 4 GLU B 98 PRO B 103 0 SHEET 2 F 4 LEU B 115 PHE B 122 -1 N VAL B 116 O TYR B 102 SHEET 3 F 4 PHE B 155 LEU B 161 -1 N PHE B 155 O PHE B 122 SHEET 4 F 4 ILE B 148 GLN B 149 -1 N ILE B 148 O GLN B 156 SHEET 1 G 4 GLN B 136 GLU B 138 0 SHEET 2 G 4 GLU B 128 ARG B 133 -1 O TRP B 131 N GLU B 138 SHEET 3 G 4 VAL B 170 GLU B 176 -1 O THR B 172 N PHE B 132 SHEET 4 G 4 LEU B 184 ARG B 189 -1 N LEU B 184 O VAL B 175 SHEET 1 H 3 VAL C 33 VAL C 38 0 SHEET 2 H 3 VAL C 82 GLY C 86 -1 N VAL C 82 O VAL C 38 SHEET 3 H 3 VAL C 118 GLU C 120 -1 O THR C 119 N ASP C 83 SHEET 1 I 3 ASP C 48 SER C 52 0 SHEET 2 I 3 ASN C 63 GLU C 67 -1 N VAL C 64 O TYR C 51 SHEET 3 I 3 LYS C 111 TYR C 115 1 O THR C 112 N ARG C 65 SHEET 1 J 5 LYS C 141 LYS C 152 0 SHEET 2 J 5 GLN C 125 GLU C 138 -1 N LEU C 126 O ASN C 151 SHEET 3 J 5 VAL C 228 THR C 236 1 N ILE C 230 O THR C 133 SHEET 4 J 5 TYR C 182 GLU C 191 -1 N GLU C 183 O THR C 235 SHEET 5 J 5 ASN C 194 ASP C 199 -1 O ASN C 194 N GLU C 191 SHEET 1 K 2 LYS C 154 THR C 156 0 SHEET 2 K 2 MET C 222 ASP C 224 -1 N VAL C 223 O VAL C 155 SSBOND 1 CYS A 107 CYS A 163 1555 1555 2.04 SSBOND 2 CYS B 15 CYS B 79 1555 1555 2.06 SSBOND 3 CYS B 117 CYS B 173 1555 1555 2.03 SSBOND 4 CYS C 93 CYS C 113 1555 1555 2.05 LINK C ACE D 803 N ALC D 804 1555 1555 1.34 LINK C ALC D 804 N ARG D 805 1555 1555 1.31 LINK C ALA D 806 N ODA D 807 1555 1555 1.32 LINK C ODA D 807 N SER D 808 1555 1555 1.33 CISPEP 1 ASN A 15 PRO A 16 0 -0.17 CISPEP 2 THR A 113 PRO A 114 0 0.30 CISPEP 3 TYR B 123 PRO B 124 0 0.13 SITE 1 AC1 24 GLN A 9 GLU A 11 PHE A 24 PHE A 32 SITE 2 AC1 24 TRP A 43 SER A 53 PHE A 54 ASN A 62 SITE 3 AC1 24 VAL A 65 ASP A 66 ASN A 69 GLU A 179 SITE 4 AC1 24 HIS B 13 TYR B 30 TYR B 47 TRP B 61 SITE 5 AC1 24 LEU B 67 LYS B 71 THR B 77 TYR B 78 SITE 6 AC1 24 HIS B 81 ASN B 82 VAL B 85 HOH D 927 CRYST1 78.343 100.168 100.175 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.012764 0.000000 0.000000 0.00000 SCALE2 0.000000 0.009983 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009983 0.00000